Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LCL161 |
Trade Name | |
Synonyms | LCL-161|LCL 161 |
Drug Descriptions |
LCL161 is a SMAC mimetic that inhibits Inhibitor of Apoptosis Protein (IAP) family proteins, potentially leading to increased tumor cell death (PMID: 21681929, PMID: 24976294, PMID: 25113756). |
DrugClasses | SMAC Mimetic 8 |
CAS Registry Number | 1005342-46-0 |
NCIT ID | C91079 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cyclophosphamide + LCL161 | Cyclophosphamide LCL161 | 0 | 1 |
LCL161 | LCL161 | 0 | 1 |
LCL161 + Paclitaxel | LCL161 Paclitaxel | 0 | 0 |
LCL161 + Spartalizumab | LCL161 Spartalizumab | 0 | 2 |
LCL161 + Topotecan | LCL161 Topotecan | 0 | 1 |